|
業務類別
|
Biotechnology |
|
業務概覽
|
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900. |
| 公司地址
| 1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024 |
| 電話號碼
| +1 201 614-3150 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.nuvectis.com |
| 員工數量
| 13 |
| Mr. Michael J. Carson |
Vice President, Finance, Principal Financial and Accounting Officer |
-- |
27/04/2026 |
| Mr. Enrique Poradosu |
Executive Vice President, Chief Scientific and Business Officer |
美元 483.38K |
27/04/2026 |
| Mr. Shay Shemesh |
Executive Vice President, Chief Development and Operations Officer |
美元 483.38K |
27/04/2026 |
| Mr. Ron Bentsur |
Chairman of the Board, Chief Executive Officer and President |
美元 653.99K |
27/04/2026 |
|
|
| Dr. Juan F Sanchez, M.D. |
Independent Director |
27/04/2026 |
| Mr. Matthew L. Kaplan |
Independent Director |
27/04/2026 |
| Mr. Ron Bentsur |
Chairman of the Board, Chief Executive Officer and President |
27/04/2026 |
| Mr. Kenneth Hoberman |
Independent Director |
27/04/2026 |
| Mr. James F. Oliviero, III |
Independent Director |
27/04/2026 |
|
|
|
|
